Prävalenz of metabolic syndrome in Germany: Results from the study of health in pomerania (SHIP);Prävalenz des Metabolischen Syndroms in Deutschland: Ergebnisse der Study of Health in Pomerania (SHIP)

Diabetologie und Stoffwechsel

Volumn 5, Issue 3, 2010, Pages 161-168

  Schipf, S ^a   Alte, D ^a   Volzke H ^a   Friedrich, N ^a   Haring, R ^a   Lohmann, T ^b   Rathmann, W ^c   Nauck, M ^a   Felix, S B ^d   Hoffmann, W ^a   John, U ^a   Wallaschofski, H ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Bereich Pneumologie Infektiologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

AGE DISTRIBUTION; ARTICLE; GERMANY; GLUCOSE BLOOD LEVEL; HUMAN; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTOR; SENSITIVITY ANALYSIS; STANDARDIZATION;

EID: 77954100914     PISSN: 18619002     EISSN: 18619010     Source Type: Journal    
DOI: 10.1055/s-0030-1247406     Document Type: Article

References (40)

1. Hanefeld M, Schaper F, Ceriello A. Geschichte und Definition(en) des metabolischen Syndroms. Internist (Berl) 2007 48 117-125
2. Neuhauser H, Ellert U. Prävalenz des metabolischen Syndroms in Deutschland: eine Sensitivitätsanalyse. 2005; http://www.egms.de/en/ meetings/gmds2005/05gmds183.shtml; 07.10.2008
3. Gami A S., Witt B J., Howard D E. et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007 49 403-414
4. Carnethon M R., Loria C M., Hill J O. et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 19852001. Diabetes Care 2004 27 2707-2715
5. Blüher M, Hammann, A. Adipostias und metabolisches Syndrom. Diabetologie 2008 3 R1-R18
6. Alberti K G., Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005 366 1059-1062 (Pubitemid 41338752)
7. Grundy S M., Cleeman J I., Daniels S R. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 2735-2752
8. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2005; http://www.idf.org/home/index.cfm?node=1429; 07.10.2008
9. Hauner H, Buchholz G, Hamann A et al. Evidenzbasierte Leitlinie Prävention und Therapie der Adipositas. Deutsche Adipositas-Gesellschaft, Deutsche Diabetes-Gesellschaft, Deutsche Gesellschaft für Ernährung, Deutsche Gesellschaft für Ernährungsmedizin. 2007
10. Eberly L E., Stamler J, Neaton J D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003 163 1077-1083
11. Nordestgaard B G., Benn M, Schnohr P et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Jama 2007 298 299-308
12. Freiberg J J., Tybjaerg-Hansen A, Jensen J S. et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. Jama 2008 300 2142-2152
13. Craig S R., Amin R V., Russell D W. et al. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000 15 395-399
14. Moebus S, Hanisch J U., Aidelsburger P et al. Impact of 4ifferent definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2007 622
15. John U, Greiner B, Hensel E et al. Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed 2001 46 186-194
16. Keil U, Liese A D., Hense H W. et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 19841992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J 1998 19 1197-1207
17. NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment PanelIII) final report.. Circulation 2002 106 3143-3421
18. Lidfeldt J, Nyberg P, Nerbrand C et al. Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study. Diabetes Obes Metab 2003 5 106-112
19. GBE Gesundheitsberichterstattung des Bundes. Neue Europäische Standardbevölkerung. 2005
20. von Elm E, Altman D G., Egger M et al. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. Internist (Berl) 2008 49 688-693 (Pubitemid 351797183)
21. Universität Ulm. Der Orale Glukosetoleranztest (OGTT). Zentrale Einrichtung Klinische Chemie. http://www.uniklinik-ulm.de/struktur/zentrale- einrichtungen/klinische-chemie/home/informationen/interpretationshilfen/ oraler-glukosetoleranztest-ogtt.html. 09.01.2009
22. Rathmann W, Haastert B, Icks A et al. Prevalence of the metabolic syndrome in the elderly population according to IDF, WHO, and NCEP definitions and associations with C-reactive protein: the KORA Survey 2000. Diabetes Care 2006 29 461-461
23. Moebus S, Hanisch J, Bramlage P et al. Regional unterschiedliche Prävalenz des metabolischen Syndroms. Deutsches Ärzteblatt 2008 105 207-213
24. Volzke H, Robinson D M., Kleine V et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005 11 1848-1853
25. Völzke H, Alte D, Neuhauser H et al. Risikopopulation Vorpommern. Ärzteblatt Mecklenburg-Vorpommern 2007 17 Jahrgang 2 49-53
26. Volzke H, Baumeister S E., Alte D et al. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. Digestion 2005 71 97-105
27. Hildrum B, Mykletun A, Hole T et al. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT2 study. BMC Public Health. 2007; 7220
28. Athyros V G., Ganotakis E S., Elisaf M et al. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005 21 1157-1159
29. Balkau B, Charles M A., Drivsholm T et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002 28 364-376
30. Neuhauser H K. The metabolic syndrome. Lancet 2005 366 1922-1923 author reply 34
31. Steveling A, Schipf S, Lerch M M. et al. Prävention von Übergewicht und Typ2 Diabetes mellitus: Was können wir tun? Arzneimitteltherapie 2008 26 323-331
32. Adams K F., Schatzkin A, Harris T B. et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71years old. N Engl J Med 2006 355 763-778
33. Moebus S, Stang A. Das metabolische Syndrom ein umstrittenes diagnostisches Konzept. Herz 2007 32 529-540
34. Levesque J, Lamarche B. The Metabolic Syndrome: Definitions, Prevalence and Management. Journal of Nutrigenetics and Nutrigenomics 2008 1 100-108 Epub 2008 Feb 20
35. Schulze J, Rothe U. Leitlinie Metabolisch-Vaskuläres Syndrom Ein gutes Beispiel für eine evidenzbasierte, praxisorientierte, interkollegiale Zusammenarbeit. Diabetes aktuell 2008 6 30-32
36. Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 2007 4Suppl BS162-BS177
37. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61prospective studies. Lancet 2002 360 1903-1913
38. Stalenhoef A F., de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 2008 19 355-361
39. Toplak H. Das Metabolische Syndrom Beginn des Tödlichen Quartetts?. Journal für Kardiologie 2005 12 (SupplementumC) 6-7
40. Bansal S, Buring J E., Rifai N et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Jama 2007 298 309-316